For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$174.35
Thesis
AstraZeneca is a diversified large-cap pharma with one of the deepest oncology pipelines in the industry — Tagrisso in lung cancer, the Enhertu antibody-drug conjugate partnered with Daiichi Sankyo, and Imfinzi in immuno-oncology — alongside a major cardio-renal-metabolic franchise led by Farxiga. That breadth across oncology, CRM, respiratory, and rare disease (Alexion) gives unusually durable, broad-based growth.
The metabolic franchise and an emerging obesity / oral-GLP-1 program add a forward leg to a company already compounding. As a high-quality, well-positioned name, the key swings are pipeline-trial outcomes, the pace of its stated revenue-growth ambition, and exposure to China and drug-pricing policy.
Catalysts
- Oncology pipeline readouts (Enhertu, Tagrisso, Imfinzi)
- Cardio-renal-metabolic and obesity program progress
- Revenue-growth ambition execution
- China demand and pricing-policy developments
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 16RegulatorySEC
AstraZeneca's Klygefa (gefurulimab) approved in the EU.
- Nov 16RegulatorySEC
AstraZeneca's Imfinzi + EV approved in US for bladder cancer
- Nov 16RegulatorySEC
AstraZeneca's Klygefa (gefurulimab) approved in the US
- Nov 16RegulatorySEC
6-K: Baxfendy recommended for approval in the EU
- Oct 30Financial resultsSEC
AstraZeneca PLC files 6-K disclosing third quarter results.
- Oct 27RegulatorySEC
ENHERTU approved in EU for HER2-positive early breast cancer (EBC).
- Oct 22RegulatorySEC
Ultomiris approved in the US for IgA nephropathy per 6-K filing.
- Oct 2PartnershipSEC
AstraZeneca and Daiichi Sankyo collaboration with Summit for Datroway.